Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
Vectors and Vector-Borne Diseases" team (Université Joseph Ki-Zerbo, Ouagadougou) led by Prof. Athanase Badolo for fieldwork, and with Dr. Noah Rose (University of California, San Diego) for expertise in
-
Grade Level 06 Salary Range $18.20-24.82/hour Type of Position Staff Position Time Status Full-Time Required Education HS Click here for more information about equivalencies: https://hr.uky.edu/employment
-
. This project is a collaboration between research institutions and Ministries of Health across Asia , building upon the existing UNITEDengue (https://www.unitedengue.org/) . You will be responsible for developing
-
The University of North Carolina at Chapel Hill | Chapel Hill, North Carolina | United States | 3 months ago
research interest is to develop adeno-associated virus (AAV) vectors to treat various diseases such as neurodegeneration disorders and liver diseases using animal and other research models, and to study the
-
06 Salary Range $16.20-24.82/hour Type of Position Staff Position Time Status Full-Time Required Education HS Click here for more information about equivalencies: https://hr.uky.edu/employment/working
-
06 Salary Range $16.20-24.82/hour Type of Position Staff Position Time Status Full-Time Required Education HS Click here for more information about equivalencies: https://hr.uky.edu/employment/working
-
06 Salary Range $16.20-24.82/hour Type of Position Staff Position Time Status Full-Time Required Education HS Click here for more information about equivalencies: https://hr.uky.edu/employment/working
-
06 Salary Range $16.20-24.82/hour Type of Position Staff Position Time Status Full-Time Required Education HS Click here for more information about equivalencies: https://hr.uky.edu/employment/working
-
(viral vector and/or extracellular vesicle-based) for myocardial regeneration. Key project goals are to develop and to deploy novel gene/cell-based therapeutics to restore cell-specific expressions
-
apply engineering biology and AI approaches to significantly accelerate the optimisation of the cell line development (CLD) processes for next-gen antibodies, focusing on optimising vector design to